{"abstract": "The federal approval of Eylea came after years of research and a total $1.2 billion in losses.", "web_url": "https://www.nytimes.com/2011/11/21/business/eylea-a-vision-drug-wins-long-sought-approval.html", "snippet": "The federal approval of Eylea came after years of research and a total $1.2 billion in losses.", "lead_paragraph": "It has three Nobel Prize winners on its board. Its chairman, P. Roy Vagelos, is a pharmaceutical industry star who ran Merck during its heyday. Its chief scientist has written frequently cited biomedical papers. ", "print_section": "B", "print_page": "3", "source": "The New York Times", "multimedia": [], "headline": {"main": "Success Long in Coming for Eylea, a Vision Treatment", "kicker": null, "content_kicker": null, "print_headline": "Success Long in Coming For a Vision Treatment", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Eyes and Eyesight", "rank": 1, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Regeneron Pharmaceuticals Inc", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Food and Drug Administration", "rank": 4, "major": "N"}, {"name": "subject", "value": "Macular Degeneration", "rank": 5, "major": "N"}], "pub_date": "2011-11-21T01:33:51+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Andrew Pollack", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/db5c81fe-7d1e-552e-b293-f2fff8579ec0", "word_count": 811, "uri": "nyt://article/db5c81fe-7d1e-552e-b293-f2fff8579ec0"}